Acquired Company

OS Therapies completed the acquisition of Advaxis Immunotherapies' listeria-based cancer immunotherapy assets from Ayala Pharmaceuticals on April 9, 2025.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland. Show more

Location: 115 Pullman Crossing Road, Grasonville, MD, 21638, United States | Website: https://ostherapies.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

51.41M

52 Wk Range

$1.12 - $3.53

Previous Close

$1.46

Open

$1.47

Volume

425,058

Day Range

$1.42 - $1.50

Enterprise Value

68.02M

Cash

1.877M

Avg Qtr Burn

-3.221M

Insider Ownership

28.00%

Institutional Own.

4.41%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OST-HER2 Details Pediatric lung metastatic osteosarcoma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OST-504 Details 2L prostate cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.